Outcomes of COVID-19 infection in multiple sclerosis and related conditions: One-year pandemic experience of the multicenter New York COVID-19 Neuroimmunology Consortium (NYCNIC)

Sylvia Klineova,Asaff Harel, Rebecca Straus Farber,Tracy DeAngelis,Yinan Zhang,Roland Hentz,Tung Ming Leung,Kathryn Fong,Tyler Smith, Richard Blanck,Lana Zhovtis-Ryerson

Multiple Sclerosis and Related Disorders（2021）

引用 16|浏览5

暂无评分

摘要

•Majority of study patients had mild COVID-19 infection without a need for hospitalization.•12.2% were hospitalized, 5.1% were critically ill, of which 15 patients (3.2%) died.•Higher neurological disability and older age independently predicted hospitalization.•Anti-CD20 therapies significantly blunt humoral responses post-infection.

查看译文

关键词

COVID-19,Multiple Sclerosis,Antibody,Anti-CD20 therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要